Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products

Berens, Christina; Heine, Annkristin; Müller, Jens; Held, Stefanie Andrea Erika; Mayer, Karin; Brossart, Peter; Oldenburg, Johannes; Pötzsch, Bernd; Wolf, Dominik; Rühl, Heiko

doi:10.1016/j.jcyt.2016.06.014

Cited by 32 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings differ from those reported in 2 previous studies, in which allogeneic products cryopreserved at single centers had mean CD34 + cell recoveries of >90%. 8 , 9 The smaller sample sizes in the earlier studies and different HPC processing and CD34 + cell quantitation practices may account for this discrepancy.…”

Section: Discussionmentioning

confidence: 91%

Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic

et al. 2020

View full text Add to dashboard Cite

Donor registries and transplantation societies recommend cryopreservation of unrelated donor hemopoietic progenitor cell (HPC) products before the recipient commences conditioning therapy to mitigate the donor and travel risks associated with the COVID-19 pandemic. However, little is known regarding the postthaw quality of such allogeneic products or the effect of precryopreservation storage and processing on these characteristics. We investigated the postthaw CD34+ cell recovery and viability of 305 allogeneic HPC products cryopreserved at 9 laboratories across Australia. Median postthaw CD34+ cell recovery was 76% and ranged from 6% to 122%. Longer transit time before cryopreservation, white cell count (WCC) during storage, and complex product manipulation before cryopreservation were independently associated with inferior postthaw CD34+ cell recovery. Longer precryopreservation transit time and WCC were also associated with inferior postthaw CD34+ cell viability. We conclude that although postthaw CD34+ cell recovery and viability of cryopreserved allogeneic HPC is generally acceptable, there is a significant risk of poor postthaw product quality, associated with prolonged storage time, higher WCC, and complex product manipulation precryopreservation. Awareness of expected postthaw recovery and practices that influence it will assist collection, processing, and transplant centers in optimizing outcomes for transplant recipients.

show abstract

Section: Discussionmentioning

confidence: 91%

Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, major components of PBMCs (T and B cells, NK cells, monocytes, dendritic cells, etc.) all survive well after cryopreservation (22,23). In terms of functionality, comparisons of fresh cell subsets with their cryopreserved counterparts also show that cell functionality is largely intact in cryopreserved cells (22), although some studies have reported some differences in cytokine responses (24).…”

Section: Discussionmentioning

confidence: 99%

Cytokine Responses to Rhinovirus and Development of Asthma, Allergic Sensitization, and Respiratory Infections during Childhood

Čustović

Belgrave

Lin

et al. 2018

Am J Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…However, DMSO-free freezing media may be an advantageous alternative for clinical applications of cryopreserved cells in the future. One recent T-cell study found that, when cryopreserved in a DMSO Preservation of cells for immunotherapy trials 951 solution, the post-thaw recovery of CD3 + CD4 + and CD3 + CD8 + subpopulations were lower than that of other subpopulations in leukapheresis products [62].…”

Section: Emerging Approachesmentioning

confidence: 99%

Preservation of cell-based immunotherapies for clinical trials

Johnson

et al. 2019

Cytotherapy

View full text Add to dashboard Cite

Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products

Cited by 32 publications

References 19 publications

Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic

Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic

Cytokine Responses to Rhinovirus and Development of Asthma, Allergic Sensitization, and Respiratory Infections during Childhood

Preservation of cell-based immunotherapies for clinical trials

Contact Info

Product

Resources

About